Connect your AI

Kura Oncology KURA Increase (decrease) in contract liabilities and current deferred income

Increase (decrease) in contract liabilities and current deferred income at other companies

SPS CommerceSPSC

$4.87M+54.2%

AvePoint, Inc.AVPT

$4.39M+4.3%

AMN HealthcareAMN

-$4.41M-312%

Q2 HoldingsQTWO

$45.49M+26.0%

Rackspace Technology, Inc.RXT

$35.6M+483%

CalixCALX

$675K-80.6%

Other financials

Income statement

Revenue$18.3M+29.5%

Gross profit$18.0M—

Operating income-$78.8M-21.8%

Net income-$73.3M-27.7%

EPS (diluted)-$0.83-25.8%

Balance sheet

Cash & equivalents$39.1M-23.8%

Total debt$24.3M+25.4%

Total equity$107.9M-70.4%

Total assets$652.6M-12.3%

Cash flow

Operating cash flow-$85.9M-19.4%

CapEx$128.0K-56.2%

Free cash flow-$86.0M-19.1%

Valuation

Market cap$919.7M+81.6%

Enterprise value$904.89M+90.7%

P/S12.8×+3.5×

Profitability

Operating margin-443.5%+103pp

Net margin-411.2%+125pp

FCF margin130.6%+74.1pp

Returns & leverage

Return on equity-124.7%-252pp

Debt / equity0.2×+0.2×

Current ratio6.1×-1.9×

Where this comes from

Reported directly by Kura Oncology in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kura Oncology's increase (decrease) in contract liabilities and current deferred income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Kura Oncology's increase (decrease) in contract liabilities and current deferred income?: Kura Oncology (KURA) reported increase (decrease) in contract liabilities and current deferred income of -$9.44M in Q1 2026.
How has Kura Oncology's increase (decrease) in contract liabilities and current deferred income changed year-over-year?: Kura Oncology's increase (decrease) in contract liabilities and current deferred income decreased by 127.3% year-over-year, from $34.59M to -$9.44M.